Author

S. Fischinger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 6 Organism:human· 4 Assay:proteomics· 4 Organism:non-human primate· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

G. Alter· 5 shared C. Atyeo· 4 shared M. J. Gorman· 3 shared S. Shin· 3 shared A. S. Menon· 2 shared C. Mann· 2 shared C.-L. Hsieh· 2 shared D. A. Lauffenburger· 2 shared

Activity by Year

2020-2022 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

G. Alter

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Hybrid immunity shifts the Fc-effector quality of SARS-CoV-2 mRNA vaccine-induced immunity

K. A. Bowman, D. Stein, S. Shin, K. G. Ferbas, N. Tobin, C. Mann, S. Fischinger, E. Ollmann Saphire, D. Lauffenberger, A. Rimoin, G. Aldrovandi, G. Alter

This study compares the humoral immune response in individuals with and without prior COVID-19 after mRNA vaccination, finding that hybrid immunity enhances Fc-effector quality rather than quantity.

bioRxiv · Jun 10, 2022Immunology

Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles

P. Kaplonek, D. Cizmeci, S. Fischinger, A.-r. Collier, T. Suscovich, C. Linde, T. Broge, C. Mann, F. Amanat, D. Dayal, J. Rhee, M. de St. Aubin, E. J. Nilles, E. R. Musk, A. S. Menon, , G. Alter

This study compares the Fc-functional antibody profiles of mRNA-1273 and BNT162b2 vaccines in a cohort of hospital staff, finding differences in epitope-specific responses and effector functions.

bioRxiv · Aug 31, 2021 · PreprintImmunology

Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19

P. Kaplonek, C. Wang, Y. Bartsch, S. Fischinger, M. J. Gorman, K. Bowman, J. Kang, D. Dayal, P. Martin, R. Nowak, C.-L. Hsieh, J. Feldman, B. Juelg, E. Nilles, E. R. Musk, , G. Alter

The paper profiles early humoral immune responses in COVID-19 patients, finding that survivors show rapid SARS-CoV-2-specific immunity linked to pre-existing OC43 immunity, while non-survivors have delayed and blunted responses.

bioRxiv · May 11, 2021 · PreprintImmunology

Sexually dimorphic placental responses to maternal SARS-CoV-2 infection

E. A. Bordt, L. L. Shook, C. Atyeo, K. M. Pullen, R. M. De Guzman, M.-C. Meinsohn, M. Chauvin, S. Fischinger, L. J. Yockey, K. James, R. Lima, L. M. Yonker, A. Fasano, S. Brigida, L. M. Bebell, , A. G. Edlow

The paper investigates sex differences in placental responses to maternal SARS-CoV-2 infection, finding sex-specific changes in interferon genes, Fc-receptor expression, and antibody transfer.

bioRxiv · Mar 29, 2021 · PreprintImmunology

Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates

J. R. Francica, B. J. Flynn, K. E. Foulds, A. T. Noe, A. P. Werner, I. N. Morre, M. Gagne, T. S. Johnston, C. Tucker, R. L. Davis, B. Flach, S. O'Connell, S. F. Andrew, E. Lamb, D. R. Flebbe, , McDermott

This study shows that an AS03-adjuvanted SARS-CoV-2 spike protein vaccine induces strong antibody responses and protects nonhuman primates from viral challenge.

bioRxiv · Mar 2, 2021 · PreprintImmunology

Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

P. S Arunachalam, A. C. Walls, N. Golden, C. Atyeo, S. Fischinger, C. Li, P. Aye, M. J. Navarro, L. Lai, V. V. Edara, K. Roltgen, K. Rogers, L. Shirreff, D. E. Ferrell, S. Wrenn, , Coffma

This study evaluates adjuvants for a subunit SARS-CoV-2 nanoparticle vaccine in non-human primates, showing durable neutralizing antibody responses and protection against infection.

bioRxiv · Feb 10, 2021 · PreprintImmunology

Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response

N. K. Routhu, S. Gangadhara, N. Cheedarla, A. Shiferaw, S. A. Rahman, A. Sahoo, P.-Y. Shi, V. D. Menachery, K. Floyd, S. Fischinger, C. Atyeo, G. Alter, M. S. Suthar, R. R. Amara

This study develops two MVA-based SARS-CoV-2 vaccines, MVA/S and MVA/S1, and finds that MVA/S induces stronger neutralizing antibodies against SARS-CoV-2 compared to MVA/S1.

bioRxiv · Jun 27, 2020 · PreprintImmunology